Join the club for FREE to access the whole archive and other member benefits.

Stealth BioTherapeutics

Biopharmaceutical company focused on the discovery and commercialization of novel therapies..

Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey and raise awareness of the unmet need our programs seek to address. We collaborate with top-tier academic and medical institutions, scientific thought leaders, and clinical key opinion leaders in developing the first generation of targeted therapies focusing on mitochondrial dysfunction as it presents in these rare genetic diseases and common diseases of aging. With these collaborative efforts, we continue to advance our platform of late-stage clinical programs and novel pipeline candidates.

Visit website:



Details last updated 07-Jan-2021

People at Stealth BioTherapeutics

Jeffrey Heier

MD, Scientific advisor, Director of Retina Research at Ophthalmic Consultants of Boston (OCB)

Reenie McCarthy

CEO at Stealth BioTherapeutics.

Hazel Szeto

Co-Founder and Director at Improving Global Health, Inc. and Scientific Founder at Stealth BioTherapeutics.

Stealth BioTherapeutics News

Longevity.Technology looks at 12 key companies running age-related disease clinical trials in 2021

Longevity Technology - 25-Feb-2022

Approaches include senotherapeutics, stem cells and mitochondria. Eye disease is a common first target.


Elamipretide: a drug to protect your eyes from AMD

Ophthalmology Times - 07-Jul-2021

Elamipritide protects your retinal cells from undergoing degeneration


Super summary of 3rd Annual Longevity Therapeutics Summit (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year

Topics mentioned on this page:
Mitochondria, Laboratory Automation